Patents by Inventor Dieter Wolfgang Hamprecht

Dieter Wolfgang Hamprecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20240141010
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • Acylated glucagon analogues
    Patent number: 11884713
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS
    Publication number: 20230257342
    Abstract: The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular diseases, such as muscular dystrophies, and neuroinflammatory diseases, including both peripheral and central disorders in human subjects, as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 17, 2023
    Inventors: Alan Duncan Robertson, Alison Dorothy Findlay, Alberto Buson, Craig Ivan Turner, Dieter Wolfgang Hamprecht, Jonathan Stuart Foot, Mandar Deodhar, Wolfgang Jarolimek, Serena Becchi, Bernard Walter Balleine, Marcella Canton, Libero Vitiello, Bert Blaauw
  • DIFLUOROHALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES, METHODS OF PREPARATION, AND USES THEREOF
    Publication number: 20220251036
    Abstract: The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer and/or scarring in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as uses thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 11, 2022
    Applicant: PHARMAXIS LTD.
    Inventors: Dieter Wolfgang HAMPRECHT, Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Angelique Elsa GRECO, Wolfgang JAROLIMEK, Wenbin ZHOU
  • Amylin analogues
    Patent number: 11382956
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: July 12, 2022
    Assignee: Zealand Pharma A/S
    Inventors: Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
  • Acylated glucagon analogue
    Patent number: 11274136
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: March 15, 2022
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20220073583
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: July 7, 2021
    Publication date: March 10, 2022
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • AMYLIN ANALOGUES
    Publication number: 20210346468
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: July 21, 2021
    Publication date: November 11, 2021
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • Acylated glucagon analogues
    Patent number: 11091528
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 17, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Glucagon analogues and methods of use
    Patent number: 11034747
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: June 15, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht
  • AMYLIN ANALOGUES
    Publication number: 20210115104
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: August 6, 2020
    Publication date: April 22, 2021
    Applicant: Zealand Pharma A/S
    Inventors: Rasmus JUST, Oliver DEMMER, Lise GIEHM, Jesper Skodborg VILLADSEN, Henrik MUNCH, Jesper Mosolff MATHIESEN, Jolanta SKARBALIENE, Maria DERYABINA, Dieter Wolfgang HAMPRECHT
  • Amylin analogues
    Patent number: 10766939
    Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 8, 2020
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Oliver Demmer, Lise Giehm, Jesper Sloth Villadsen, Henrik Munch, Jesper Mosolff Mathiesen, Jolanta Skarbaliene, Maria Deryabina, Dieter Wolfgang Hamprecht
  • AMYLIN ANALOGUES
    Publication number: 20200188485
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: October 25, 2019
    Publication date: June 18, 2020
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20200157168
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 12, 2019
    Publication date: May 21, 2020
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • ACYLATED GLUCAGON ANALOGUE
    Publication number: 20200087372
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 13, 2019
    Publication date: March 19, 2020
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Leo THOMAS
  • Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 10501440
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Iain Lingard, Dieter Wolfgang Hamprecht, Remko Alexander Bakker, Matthias Eckhardt, Andreas Gollner, Joerg P. Hehn, Elke Langkopf, Holger Wagner, Bernd Wellenzohn, Dieter Wiedenmayer
  • Acylated glucagon analogues
    Patent number: 10457714
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 29, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Acylated glucagon analogue
    Patent number: 10336802
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 2, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
  • AMYLIN ANALOGUES
    Publication number: 20190134159
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 9, 2019
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • Glucagon analogues
    Patent number: 10253081
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist